The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2020 | Prognostic significance of PET-CT status after first line immuno-chemotherapy for FL
Judith Trotman, MBChB, FRACP, FRCPA, of the University of Sydney School of Medicine, Sydney, Australia, discusses the prognostic value of PET-CT status after long-term follow-up of follicular lymphoma (FL) patients enrolled in the GALLIUM study (NCT01332968) which aimed to evaluate the efficacy of first-line immunochemotherapy. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
